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Background: Galanin is a key modulator of nociception, and it is also required for the developmental survival of a
subset of C-fibre sensory neurons which are critical to the mediation of neuropathic and inflammatory pain.
However, the potential modulatory roles played by galanin, or the galanin-dependent neurons, in pruritoceptive
mechanisms underlying the sensation of itch have not been investigated.
Findings: Here we report that mice carrying a loss-of-function mutation in the galanin gene (Gal-KO) show no
differences in spontaneous behavioural itch responses compared to wild-type (WT) controls. Similarly, the responses
to a range of pruritogens are not significantly different between the two genotypes.
Conclusions: These results suggest that neither galanin expression, nor the galanin-dependent subpopulation of
sensory neurons is required for itch-related behaviours.
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Introduction
Itch and pain are complex unpleasant sensory expe-
riences that provoke aversive yet protective responses.
Like pain, itch may become a chronic pathological con-
dition. However, the relationship between the neuronal
circuits that mediate itch and pain is unclear. Emerging
evidence has identified specific subpopulations of pepti-
dergic and non-peptidergic peripheral sensory C-fibre
neurons, some of which constitute a proportion of the
nociceptive neuronal population, that appear to mediate
the sensation of itch [1-3]. Several neuropeptides includ-
ing gastrin-related peptide (GRP) [4], calcitonin gene-
related peptide [5] and substance P [6] have been shown
to modulate the neurotransmission of itch, in addition
to glutamate [7]. Further, genetic ablation of MrgprD
neurons which account for approximately 90% of cuta-
neous non-peptidergic neurons does not appear to affect
behavioural responses to several pruritogens [8], implying
an important role for the peptidergic population in itch
signalling.
Given the similarities between chronic itch and pain
[9], and apparently similar subpopulations of sensory* Correspondence: D.Wynick@bristol.ac.uk
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reproduction in any medium, provided the orneurons thought to mediate these functional pathways,
the two circuits may be related, if not overlapping. Tar-
geted disruption of the GRP and TLR7 receptors and
the chromosomal locus encoding 12 Mrgpr genes all at-
tenuate itch induced by various pruritogens, but have no
significant effect on nociceptive, neuropathic or inflam-
matory pain behaviours [4,10,11]. In contrast, abolition
of VGLUT2-dependent synaptic glutamate release from
nociceptors greatly enhances chronic itching and signifi-
cantly reduces neuropathic and inflammatory pain beha-
viours [12].
Taken together, the above data provide evidence that
some pruritogens are dependent on subsets of peptider-
gic C-fibre neurons for their effects, though whether
these circuits overlap with, or are distinct from, those
that mediate neuropathic pain is still uncertain. To ad-
dress this question, we studied mice with a targeted de-
letion of the neuropeptide galanin (Gal-KO) which lose
a subset of small diameter unmyelinated peptidergic sen-
sory neurons shortly after birth [13].
Galanin is expressed during development by the
majority of dorsal root ganglion (DRG) neurons, from
E13 until shortly after birth [14], after which it is down-
regulated. In the adult, it is expressed in about 5%
of, predominantly C-fibre, DRG neurons [15]. Higher
levels are expressed in primary afferent terminals andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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several brain areas important for pain processing [16].
After nerve injury, galanin in the DRG increases signifi-
cantly in about 30% of sensory neurons, and moderately
increases in the dorsal horn [17]. Intrathecal administra-
tion of low dose galanin has modest facilitatory effects
on nociception, whereas higher doses cause marked
inhibition. In models of nerve injury when endogenous
levels of galanin are high, the neuropeptide inhibits pain
behaviour [18,19].
Galanin also plays a developmental cell survival role in
the DRG. In the absence of galanin, a subset of peptider-
gic C-fibre neurons (13% of all DRG neurons) are lost by
apoptosis shortly after birth [13]. These neurons seem to
be pivotal to the development of neuropathic and in-
flammatory pain behaviours, which are absent or greatly
diminished in Gal-KO mice [20-22].
In the present study we asked whether itch behaviours
to a variety of pruritogens known to act on different
subpopulations of primary sensory neurons are altered
in the Gal-KO animals.Methods
Mice
Gal-KO mice were generated as previously described
[13] and maintained on the inbred 129OlaHsd strain
with identical strain-matched wild-type (WT) controls.
10–12 weeks old male mice were used for all experiments.
All work performed conformed to United Kingdom Home
Office legislation (Scientific Procedures Act 1986). Proce-
dures were conducted in accordance with UK Home
Office principles of laboratory animal care.Itch-related behaviours
Mice were habituated to the testing environment
and subsequent behaviour recorded by video camera.
Basal spontaneous scratching behaviour was monitored
then mice were injected intradermally, using a BD
Microfine 0.3 ml syringe with 29G needle, with 50 μl
PBS to determine scratching responses to vehicle. Sub-
sequently, the following pruritogens were injected in a
volume of 50 μl: 100 μg (650 nmol) compound 48/80;
100 μg (900 nmol) histamine; 25 ng (10 pmol)
endothelin-1; 60 μg (196 nmol) α-methyl-serotonin;
100 μg (152 nmol) SLIGRL-NH2; 200 μg (388 nmol)
chloroquine; n = 8 for each group. Numbers of scratch-
ing bouts were scored in 5 min increments over the
30 or 60 min period by an observer blind to the geno-
type tested. A scratching bout was defined as one or
more rapid hind paw movements directed at the injec-
tion site, ending with the mouse placing its hind paw
back on the floor.Cheek model of itch or pain
Basal wiping and scratching behaviour was monitored
for 30 min prior to cheek injection of 20 μg capsaicin or
vehicle (10% ethanol, 10% Tween 80 in PBS) in 20 μl.
Numbers of forelimb wipes or hindlimb scratches direc-
ted at the injection site were counted in 5 min incre-
ments over 20 min; n = 8 for the vehicle-injected group
and n = 16 for the capsaicin-injected group.Data analysis
Unpaired t-tests were used to compare behavioural data
from WT and Gal-KOs. Data are presented as mean ±
SEM. P < 0.05 was considered significant.Results
The scratching reflex in rodents in response to intrader-
mal or subcutaneous injection of a pruritogen is a well
characterised behavioural correlate of itch [23]. Prurito-
gens may act directly on sensory primary afferents via
specific receptors to activate itch and/or indirectly via
non-neuronal cells in the skin. In this study the number
of spontaneous scratch bouts, as well as the number eli-
cited by various pruritogens, were measured in strain-,
sex- and age-matched WT and Gal-KO mice.
Gal-KO and WT mice both showed minimal sponta-
neous scratching behaviours. Similarly, no scratching
behaviours in either genotype were observed following a
vehicle injection of PBS.
Compound 48/80 promotes mast cell degranulation
and thus predominantly elicits itch indirectly via the re-
lease of several pruritogens from mast cells, mainly his-
tamine. Over a 30 min period, WT mice exhibited 124 ±
13 scratch bouts and Gal-KO mice 156 ± 19 (p = 0.193)
(Figure 1A).
Histamine acts via H1 and H4 receptors, both
expressed by C-fibre neurons in the DRG. Histamine eli-
cited very weak itch responses of 13 ± 4 and 10 ± 3
scratch bouts in WT and Gal-KO mice, respectively
(p = 0.683) (Figure 1B).
α-Methyl-5-hydroxytryptamine, a serotonin receptor
agonist, targets the 5-HT2 metabotropic receptor. It eli-
cited robust scratching in WT mice (135 ± 11 bouts).
Less scratching was seen in Gal-KO mice (103 ± 12
bouts), but the difference was not statistically significant
(p = 0.07) (Figure 1C).
Endothelin-1 induces itch via activation of ETA recep-
tors. It induced similar scratching behaviour in WT
(108 ± 45) and Gal-KO mice (153 ± 43; p = 0.492)
(Figure 1D).
SLIGRL-NH2 is a PAR-2 agonist, but may induce itch
through activation of MrgprC11 [24] in the non-
peptidergic population of C-fibre neurons. SLIGRL-NH2
induced comparable scratching responses in both WT
Figure 1 Pruritogen-induced itch-related behaviour in WT and Gal-KO mice. Numbers of scratching bouts were measured in WT and Gal-KO
mice after intradermal injection of: (A) compound 48/80; (B) histamine; (C) α-methyl serotonin; (D) endothelin-1; (E) SLIGRL-NH2 and (F) chloroquine.
Results are presented as means ± SEM.
Figure 2 Capsaicin-induced pain or itch in WT and Gal-KO mice.
Pain (forelimb wiping) and itch (hindpaw scratching)-related
behaviours were measured after intradermal cheek injection of
vehicle or capsaicin. Results are presented as means ± SEM.
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(Figure 1E).
Chloroquine also activates a histamine-independent
itch pathway, which has recently been shown to be
mediated via activation of MrgprA3 expressed by non-
peptidergic C-fibre neurons [25]. Again, there was no
significant difference in itch-related behaviours in WT
and Gal-KO mice (134 ± 45 vs 173 ± 54; p = 0.658)
(Figure 1F).
Although it is clear that galanin is involved in the modu-
lation of pain, its precise mode of action via its receptors,
GalR1 and GalR2, is complex and remains incompletely
understood. Most current evidence suggests that galanin
has an inhibitory role in nociception, mediated post-
synaptically via the hyperpolarisation of GalR1-expressing
glutaminergic dorsal horn neurons. Conversely, galanin
appears to activate GalR2 pre-synaptically. Both GalR1
and GalR2 mRNA are expressed in partially overlapping
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little GalR2 expression in intrinsic dorsal horn neurons.
GalR2 activation has both facilitatory and inhibitory
effects on neurotransmission, depending on the local
concentration of galanin. However, in models of neu-
ronal damage, when endogenous levels of galanin are
increased, its inhibitory role is predominant. As well as
being expressed in DRG neurons, galanin is also present
in a small population of inhibitory interneurons, but
their role in the modulation of acute or chronic pain
is unknown. Determining the precise distribution of
GalR1 and GalR2 has been hampered by a lack of specific
antibodies. Furthermore, a paucity of receptor-specific
agonist and antagonists had made the elucidation of the
role of galanin and its receptors in pain and itch circuitry
difficult.
Current data suggest that pain and itch circuits are an-
tagonistic: Pain appears to suppress itch and inhibition
of pain evokes itch. Therefore, on the one hand, it might
be expected that a lack of the neuromodulatory actions
of galanin may reduce itch, as might a loss of a subset of
C-fibre neurons, if they express molecules required for
mediating pruritic behaviours. Conversely, the loss of a
subset of galanin-dependent nociceptors in the Gal-KO
that mediate chronic neuropathic and inflammatory pain
behaviours, may enhance itch. Lastly, it is possible that
the neuromodulatory and survival roles played by gala-
nin may have opposing effects on itch and thus mask a
subtle phenotype in the Gal-KO mice.
To further study the role of the galanin-dependent
sensory neuron population in the modulation of itch, we
used the cheek model of itch/pain [26]. This model
allows the behavioural differentiation of itch and pain;
substances which elicit pain cause enhanced forepaw
wiping of the injection site, whereas substances which
elicit itch cause hindpaw scratching. Cheek injection of
capsaicin caused wiping behaviour but no scratching be-
haviour. There was no significant difference between
WT and Gal-KO mice (p = 0.743) (Figure 2). Previously
we have shown that Gal-KOs have deficits in pain-like
behaviour in response to intraplantar injection of forma-
lin or carrageenan [22]. It is likely that these chronic in-
flammatory agents act through a range of different
mechanisms to induce pain-like behavioural responses.
For example, capsaicin has a short-acting effect when
injected in the cheek, acting through TRPV1, whereas
the first phase of the formalin response is mediated by
direct activation of nociceptors via TRPA1 and the se-
cond phase reflects central sensitisation. Therefore dif-
ferent injection sites, behavioural outcomes and modes
of action of the inflammatory agents may explain the ab-
sence of a difference in acute nociception in the Gal-KO
and WT mice. Further, since the effects of capsaicin are
mediated via TRPV1, which is expressed in about half ofpeptidergic nociceptors, it is also possible that the
remaining TRPV1-positive neurons in the Gal-KO are
sufficient to induce the maximal wiping response in the
cheek model of itch/pain.
In summary, our data does not support a tonic role for
galanin in modulating itch in the adult. Similarly, the
galanin-dependent population of peptidergic neurons
which we have shown to be critical for mediating the full
expression of neuropathic and inflammatory pain beha-
viours appear to be dispensable for itch. These findings
are therefore consistent with the hypothesis that itch
and neuropathic pain are mediated by distinct and spe-
cific signalling pathways.
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